Shares
Value
Common
Stocks
–
89.9%
Consumer,
Non-cyclical
–
65.8%
Adaptimmune
Therapeutics
PLC,
ADR*
............................................
150,000
$
163,500
Adicet
Bio,
Inc.*
...............................................................
26,900
154,944
Agios
Pharmaceuticals,
Inc.*
....................................................
5,792
133,042
Akero
Therapeutics,
Inc.*
.......................................................
59,777
2,287,068
Allogene
Therapeutics,
Inc.*
.....................................................
245,000
1,210,300
Annexon,
Inc.*
................................................................
653,483
2,515,909
Applied
Therapeutics,
Inc.*
......................................................
2,382,621
1,932,544
ATAI
Life
Sciences
NV*
.........................................................
140,000
253,400
Athira
Pharma,
Inc.*
...........................................................
1,390,148
3,475,370
Avidity
Biosciences,
Inc.*
.......................................................
125,000
1,918,750
Chinook
Therapeutics,
Inc.*
.....................................................
25,000
578,750
Cybin,
Inc.*
..................................................................
500,000
192,500
Eiger
BioPharmaceuticals,
Inc.*
..................................................
1,099,653
986,279
Fulcrum
Therapeutics,
Inc.*
.....................................................
465,000
1,325,250
Heron
Therapeutics,
Inc.*
.......................................................
306,590
462,951
Kura
Oncology,
Inc.*
...........................................................
80,000
978,400
Kymera
Therapeutics,
Inc.*
......................................................
10,532
312,063
Madrigal
Pharmaceuticals,
Inc.*
..................................................
14,294
3,462,864
Marinus
Pharmaceuticals,
Inc.*
..................................................
150,000
1,035,000
Mirum
Pharmaceuticals,
Inc.*
....................................................
70,000
1,681,400
Omega
Therapeutics,
Inc.*
......................................................
27,859
167,990
Phathom
Pharmaceuticals,
Inc.*
..................................................
237,935
1,698,856
Replimune
Group,
Inc.*
.........................................................
150,000
2,649,000
Sage
Therapeutics,
Inc.*
........................................................
50,030
2,099,259
Seres
Therapeutics,
Inc.*
.......................................................
550,626
3,122,049
Stoke
Therapeutics,
Inc.*
.......................................................
122,796
1,022,891
Sutro
Biopharma,
Inc.*
.........................................................
120,000
554,400
TScan
Therapeutics,
Inc.*
.......................................................
546,916
1,148,524
X4
Pharmaceuticals,
Inc.*
.......................................................
400,000
348,000
37,871,253
Energy
–
24.1%
Plains
GP
Holdings
LP,
Class
A*
..................................................
1,054,397
13,833,689
Total
Common
Stocks
(Cost
$68,908,553)
........................................................
51,704,942
Exchange-Traded
Funds
–
3.6%
iShares
Floating
Rate
Bond
ETF
.................................................
4,500
226,755
SPDR
Bloomberg
Investment
Grade
Floating
Rate
ETF
...............................
61,480
1,870,837
Total
Exchange-Traded
Funds
(Cost
$2,112,739)
..................................................
2,097,592
Closed-End
Funds
–
3.2%
Kayne
Anderson
Energy
Infrastructure
Fund
(Cost
$1,930,200)
...........................................................
212,238
1,833,736
Money
Market
Funds
–
2.5%
Fidelity
Investments
Money
Market
Treasury
Only
Portfolio
-
Class
I,
4.41%(a)
(Cost
$1,431,164)
...........................................................
1,431,164
1,431,164
